House Appropriations Bill Misses the Mark on ID Programs

House Appropriations Bill Misses the Mark on ID Programs

The House FY 2025 Labor, Health and Human Services and State and Foreign Operations appropriations bills largely flat fund antimicrobial resistance programs at FY 2024 levels even as AMR grows as a serious public health threat. While IDSA appreciates the modest increase for the Centers for Diseases Control and Prevention ID and opioids program in the LHHS bill, we are very disappointed that the measure did not provide any funding for the Bio-Preparedness Workforce Pilot Program at the Health Resources and Services Administration, a bipartisan effort to close growing ID workforce gaps that endanger patient care, public health and preparedness.

IDSA is extremely concerned that the LHHS bill includes a proposal to divide the National Institute of Allergy and Infectious Diseases into two separate institutes with reduced overall funding. This is part of a larger, unvetted NIH consolidation proposal that has not yet received stakeholder input and therefore should not have been included in the bill.

Information on funding for HIV programs can be found here.

Additional details on the appropriations bills are below. It is unclear how or when the Senate will move forward with their FY 2025 funding bills, and final funding legislation is not likely to pass until after the November elections. IDSA continues to urge Congress to provide sufficient funding in FY 2025 for ID programs.

Labor, Health and Human Services Appropriations Bill

• $197 million for CDC's Antibiotic Resistance Solutions Initiative, level with FY 2024
• $3.315 billion for a new, proposed National Institute of Infectious Diseases at the National Institutes of Health, a $3.315 cut compared to NIAID FY2024 funding; this reflects an unvetted NIH consolidation proposal, which splits NIAID into two separate institutes, with allergy research in a separate institute from ID research. This includes level funding of $565 million for AMR research, level with FY2024.
• $1.1 billion for the Biomedical Advanced Research and Development Authority, a $85 million increase over FY 2024
• $563 million for the Center for Global Health, a $128 million decrease below FY 2024, due to the elimination of Global HIV/AIDS funding
• $24 million in funding for the National Healthcare Safety Network at CDC, level with FY 2024
• $40 million in funding for the Advanced Molecular Detection initiative at CDC, level with FY 2024
• $29.079 million for infectious diseases and opioid activities at CDC, a $6.079 million increase over FY 2024
• $95.162 million for NIH's Fogarty International Center, level with FY 2024
• $681.9 million for CDC's Immunizations Program, level with FY 2024
• Elimination of CDC's Ready Response Enterprise Data Integration and Center for Forecasting, a $55 million cut from FY 2024

State and Foreign Operations Appropriations Bill

• No specified funding level for global health security at USAID that focuses on pandemic prevention, detection and response. While there is funding available in USAID accounts that could fund global health security, it is unclear whether the program will receive an increase or decrease over FY 2024.
• $1.25 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria, a $400 million cut below the FY 2024 enacted level related to a funding match requirement that limits the amount the U.S. can contribute - a cap of 33% of total contributions to the Global Fund for all other donors
• $4.395 billion for the President's Emergency Plan for AIDS Relief, level with FY 2024
• $394.5 million for the USAID global TB program, level with FY 2024 enacted level